Antigens Patents (Class 435/69.3)
-
Patent number: 7255863Abstract: The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response against Group A streptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A streptococci.Type: GrantFiled: January 16, 2004Date of Patent: August 14, 2007Assignee: University of Tennessee Research FoundationInventor: James B Dale
-
Patent number: 7244712Abstract: The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bacterial strains. The present invention also relates to methods of treatment and pharmaceutical compositions that utilize or comprise one or more of aminoglycoside compounds provided by the invention.Type: GrantFiled: September 14, 2004Date of Patent: July 17, 2007Assignee: President and Fellows of Harvard CollegeInventor: Robert R. Rando
-
Patent number: 7244580Abstract: The present invention relates to identification of polypeptides useful for generating antibodies specific for non-human IgE, particularly equine IgE. The invention, therefore, also relates to antibodies that specifically bind to IgE and methods to detect IgE using the antibodies. The invention also provides a kit for detection of IgE.Type: GrantFiled: November 8, 2001Date of Patent: July 17, 2007Assignee: The Regents of the University of CaliforniaInventors: Laurel J. Gershwin, Howard David Pettigrew, Warren V. Kalina
-
Patent number: 7241582Abstract: This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied to both the diagnosis and prevention of PRRSV infection.Type: GrantFiled: July 5, 2005Date of Patent: July 10, 2007Assignee: MJ Biologics, Inc.Inventors: Han-Soo Joo, Eugenio P. Mende
-
Patent number: 7241742Abstract: The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer.Type: GrantFiled: October 31, 2001Date of Patent: July 10, 2007Assignee: MGI PHARMA Biologics, Inc.Inventors: Nazneen Aziz, Mary Lynne Hedley, Robert G. Urban, Andrew J. Tomlinson, Geoffrey Cole
-
Patent number: 7238345Abstract: Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease.Type: GrantFiled: June 5, 1995Date of Patent: July 3, 2007Assignee: Wyeth Holdings CorporationInventors: Robert C. Seid, Jr., Peter R. Paradiso, Jan T. Poolman, Peter Hoogerhout, Emmanuel J. H. J. Wiertz, Peter van der Ley, John Edward Heckels, Ian Nicholas Clarke
-
Patent number: 7235243Abstract: Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: July 1, 2005Date of Patent: June 26, 2007Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann Gray, Karen S. Biscardi, Lorne F. Erdile, Bruno Guy
-
Patent number: 7226588Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, or the endotoxin isolated therefrom, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: GrantFiled: March 23, 2005Date of Patent: June 5, 2007Assignees: University of Iowa Research Foundation, The Regents of the University of CaliforniaInventors: Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Bradford W. Gibson
-
Patent number: 7227010Abstract: Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4° C. for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A.Type: GrantFiled: November 6, 2001Date of Patent: June 5, 2007Assignee: United States of America as Represented by the Secretary of the ArmyInventor: Leonard A. Smith
-
Patent number: 7223412Abstract: The present invention relates to a method of producing recombinant modified Staphylococcal toxin having improved stability, comprising the steps of preparing a modified toxin in which a specific amino acid sequence is substituted and a vector for expressing the modified toxin, and culturing E. coli transformed with the vector, and a use thereof for the vaccine.Type: GrantFiled: October 31, 2000Date of Patent: May 29, 2007Assignee: LG Chem-Investment Ltd.Inventors: Hong-Kyun Lee, Yong-Ho Park, Kyu-Boem Han, Byoung-Sun Chang, Yong-Jun Lee
-
Patent number: 7220419Abstract: Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.Type: GrantFiled: February 21, 2003Date of Patent: May 22, 2007Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Douglas R. Lowy, John T. Schiller, Reinhard Kirnbauer
-
Patent number: 7217541Abstract: Disclosed herein are methods for making large amounts of highly pure colonization factors. The methods of the present invention differ from prior art methods in that host cells which express the colonization factor of interest are cultured in media comprising more than about 50 ?g/l of an antibiotic, the media is centrifuged and then filtered with a 0.2 ?m filter tangential flow cartridge and a 300,000 MW cut-off filter, and a divalent cation is added. As disclosed herein the colonization factors made by the method of the present invention may be used in pharmaceutical compositions and methods for treating or preventing enterotoxigenic Escherichia coli infections.Type: GrantFiled: February 24, 2003Date of Patent: May 15, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Frederick J. Cassels, James F. Wood
-
Patent number: 7211408Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: GrantFiled: June 16, 2003Date of Patent: May 1, 2007Assignee: Merck Patent GmbHInventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
-
Patent number: 7205101Abstract: Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.Type: GrantFiled: May 17, 1995Date of Patent: April 17, 2007Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Paul A. Luciw, Dino Dina
-
Patent number: 7186527Abstract: The present invention provides isolated nucleic acid sequences and expression vectors encoding the Goodpasture antigen binding protein (GPBP), substantially purified GPBP, antibodies against GPBP, and methods for detecting GPBP.Type: GrantFiled: October 11, 2002Date of Patent: March 6, 2007Inventor: Juan Saus
-
Patent number: 7176286Abstract: The invention described herein relates to a method for identifying antigen fragments of Toxoplasma gondii proteins, and their use as diagnostic and immunogenic agents. Said method is implemented by means of selection of DNA fragments libraries of the parasite with sera of subjects who have been infected, using the phage display technique, and is characterised in that it uses the expression/exposure vector ?KM4. The method allows also to identify antigen fragments related to the time of the infection.Type: GrantFiled: March 18, 2003Date of Patent: February 13, 2007Assignee: Kenton S.R.L.Inventors: Nicola Gargano, Elisa Beghetto, Manlio Di Cristina, Franco Felici
-
Patent number: 7166287Abstract: The invention relates to post-transfusional non-A non-B hepatitis viral polypeptide, DNA sequences encoding such viral polypeptide, expression vectors containing such DNA sequences, and hosts transformed by such expression vectors. The invention also relates to the use of such polypeptides in diagnostic assays and vaccine formulations.Type: GrantFiled: September 18, 2000Date of Patent: January 23, 2007Assignee: Glaxo Wellcome Inc.Inventors: Peter E. Highfield, Brian C. Rodgers, Richard S. Tedder, John A. J. Barbara
-
Patent number: 7157245Abstract: Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal Neisseria or an extract of a commensal Neisseria. Further methods and compositions comprise commensal Neisseria which express genes from virulent strains of Neisseria and/or heterologous gene products from non-neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.Type: GrantFiled: August 31, 2001Date of Patent: January 2, 2007Assignee: Health Protection AgencyInventors: Andrew Robinson, Andrew Richard Gorringe, Michael John Hudson, Philippa Bracegirdle, John Simon Kroll, Paul Richard Langford, Steven Anthony Rochford Webb, Keith Cartwright, Cliona Anne O'Dwyer, Karen Margaret Reddin
-
Patent number: 7153510Abstract: The invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time, successfully allows the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA, by a method comprising expression of the full-length positive-strand vesiculovirus antigenomic RNA in host cells. The recombinant vesiculoviruses do not cause serious pathology in humans, can be obtained in high titers, and have use as vaccines. The recombinant vesiculoviruses can also be inactivated for use as killed vaccines.Type: GrantFiled: May 4, 1995Date of Patent: December 26, 2006Assignee: Yale UniversityInventor: John K. Rose
-
Patent number: 7144997Abstract: It is shown here that hedgehog proteins possess novel activities beyond phenotype specification. Using cultures derived from the embryonic day 14.5 (E14.5) rat ventral mesencephalon, we show that hedgehog is also trophic for dopaminergic neurons. Interestingly, hedgehog not only promotes dopaminergic neuron survival, but also promotes the survival of midbrain GABA-immunoreactive (GABA-ir) neurons.Type: GrantFiled: July 24, 1997Date of Patent: December 5, 2006Assignee: Curis, Inc.Inventors: Ningning Miao, Monica Wang, Nagesh K. Mahanthappa, Kevin Pang
-
Patent number: 7144998Abstract: Recombinant polypeptides are prepared using novel nucleic acids with transcription promoter activity. The recombinant cells containing said nucleic acids are described. A novel method for preparing antigens or antigen fragments, in particular bacterial toxins, preferably Clostridum toxins, for preparing immunogenic and/or vaccine compositions is also described.Type: GrantFiled: March 20, 2000Date of Patent: December 5, 2006Assignee: Institut PasteurInventors: Maryse Gibert, Michel-Robert Popoff
-
Patent number: 7144712Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.Type: GrantFiled: July 30, 2003Date of Patent: December 5, 2006Assignee: Vaccine Research Institute of San DiegoInventors: David R. Milich, Jean-Noel Billaud
-
Patent number: 7144578Abstract: Recombinant viruses containing DNA coding for a rabies virus antigen, such as rabies virus G are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom are useful for eliciting an immunological against rabies virus, and, the gene products and antibodies elicited thereby are useful in assays.Type: GrantFiled: September 13, 2001Date of Patent: December 5, 2006Assignee: Connaught Technology CorporationInventors: Enzo Paoletti, James Tartaglia, Jill Taylor, Russell Gettig
-
Patent number: 7141244Abstract: This invention provides polypeptides of Helicobacter pylori cytotoxin associated immunodominant (CAI) antigen. The invention also provides prophylactic and therapeutic vaccines comprising polypeptides of Helicobacter pylori CAI antigen, and methods for their preparation. The invention also provides methods of treatment of Helicobactor pylori infection using these vaccines.Type: GrantFiled: July 26, 1999Date of Patent: November 28, 2006Assignee: Chiron SRLInventors: Antonello Covacci, Massimo Bugnoli, John Telford, Giovanni Macchia, Rino Rappuoli
-
Patent number: 7129337Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2i, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.Type: GrantFiled: October 23, 1995Date of Patent: October 31, 2006Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7122197Abstract: The invention provides BASB020 polypeptides and polynucleotides encoding BASB020 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: May 7, 1999Date of Patent: October 17, 2006Assignee: SmithKline Beecham Biologicals S.A.Inventor: Joelle Thonnard
-
Patent number: 7118749Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.Type: GrantFiled: January 14, 2002Date of Patent: October 10, 2006Assignee: Connaught Laboratories LimitedInventors: Sheena M. Loosmore, Robin E. Harkness, Anthony B. Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew D. Murdin, Michel H. Klein
-
Patent number: 7115268Abstract: This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates to peptides derived from homologous sequences of the family of staphylococcal and streptococcal toxins, which may be polymeric, and carrier-conjugates thereof. The invention also relates to serum antibodies induced by the peptides and carrier-conjugates and their use to prevent, treat, or protect against the toxic effects of most, if not all, of the staphylococcal and streptococcal toxins. The invention also relates to diagnostic assays and kits to detect the presence of staphylococcal and streptococcal toxins, or antibodies thereto. The invention also relates isolated and purified to nucleic acids encoding the peptides of the invention and transformed host cells containing those nucleic acids.Type: GrantFiled: June 18, 1999Date of Patent: October 3, 2006Assignee: The Rockefeller UniversityInventors: Jason D. Bannan, Kumar Visvanathan, John B. Zabriskie
-
Patent number: 7115725Abstract: Disclosed is DNA encoding diphtheria toxin polypeptides having multiple mutations, which render the polypeptides useful as vaccines.Type: GrantFiled: August 20, 2002Date of Patent: October 3, 2006Assignee: President and Fellows of Harvard CollegeInventor: R. John Collier
-
Patent number: 7115269Abstract: The present invention is directed to an attenuated Salmonella comprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuated Salmonella comprising the eukaryotic expression vector.Type: GrantFiled: October 18, 1999Date of Patent: October 3, 2006Assignee: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)Inventors: Ayub Darji, Carlos A. Guzman, Kenneth Timmis, Siegfried Weiss, Birgit Gerstel, Trinad Chakraborty, Petra Wachholz, Jürgen Wehland
-
Patent number: 7105316Abstract: LbpB polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing LbpB polypeptides and polynucleotides in the design of protocols for the treatment of neisserial disease, among others, and diagnostic assays for such conditions.Type: GrantFiled: December 12, 2003Date of Patent: September 12, 2006Assignees: University of Utrecht, Technology FoundationInventors: Annika Margareta Pettersson-Fernholm, Johannes Petrus Maria Tommassen
-
Patent number: 7101989Abstract: DsrA is an outer membrane protein of H. ducreyi that confers serum resistance to the bacteria. Isolated polynucleotides encoding the protein, end expression vectors and host cells encoding the same, are described. Also described is a mutant H. ducreyi strain that does not express DsrA. Vaccines against H. ducreyi and methods of using the same are also described.Type: GrantFiled: July 7, 2000Date of Patent: September 5, 2006Assignee: University of North Carolina at Chapel HillInventor: Christopher Elkins
-
Patent number: 7094576Abstract: Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.Type: GrantFiled: March 30, 2001Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Victor C. W. Tsang, Ryan M. Greene, Patricia P. Wilkins, Kathy Hancock
-
Patent number: 7094571Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in the periplasm of gram negative bacteria and mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the outer surface-expression of ligand fusion proteins employed with phage display.Type: GrantFiled: July 15, 2003Date of Patent: August 22, 2006Assignee: The Board of Regents of The University of Texas SystemInventors: Barrett R. Harvey, George Georgiou, Brent L. Iverson
-
Patent number: 7094411Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural protein genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.Type: GrantFiled: February 16, 2001Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Richard M. Kinney, Claire Y. H. Kinney, Duane J. Gubler, Siritorn Butrapet, Natth Bhamarapravati
-
Patent number: 7094391Abstract: Mucosal administration of OspA and compositions therefor are disclosed and claimed. More particularly, oral administration of OspA and compositions therefor for eliciting an immunological response against Borrelia burgdorferi, such as a protective response preventive of Lyme disease are disclosed and claimed. Thus, oral Lyme disease vaccines or immunological compositions and methods of use are disclosed and claimed.Type: GrantFiled: January 19, 1996Date of Patent: August 22, 2006Assignee: The University of Texas SystemInventors: Alan G. Barbour, Catherine J. Luke
-
Patent number: 7087234Abstract: The present invention relates to multivalent recombinant raccoon poxviruses, containing more than one exogenous gene inserted into either the thymidine kinase gene, the hemagglutinin gene, or a combination thereof. Disclosed is the use of the multivalent recombinant raccoon poxviruses as vaccines to immunize felines against subsequent challenge by feline pathogens. Also disclosed is a method of making a multivalent recombinant raccoon poxvirus by a recombination process involving the construction of an insertion vector into which the exogenous genes are inserted, and flanking the inserted genes are sequences which can recombine into the raccoon poxvirus thymidine kinase gene, or the hemagglutinin gene, or a combination thereof; introducing both the insertion vector containing the exogenous genes, and raccoon poxvirus into susceptible host cells; and selecting the recombinant raccoon poxvirus from the resultant plaques.Type: GrantFiled: June 4, 2001Date of Patent: August 8, 2006Assignees: Cornell Research Foundation, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Fred W. Scott, Christopher K. Ngichabe, Liangbiao Hu, Joseph J. Esposito
-
Patent number: 7083945Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating binding proteins capable of binding small molecules and peptides via “display-less” library screening. In the technique, libraries of candidate binding proteins, such as antibody sequences, are expressed in soluble form in the periplasmic space of gram negative bacteria, such as Escherichia coli, and are mixed with a labeled ligand. In clones expressing recombinant polypeptides with affinity for the ligand, the concentration of the labeled ligand bound to the binding protein is increased and allows the cells to be isolated from the rest of the library. Where fluorescent labeling of the target ligand is used, cells may be isolated by fluorescence activated cell sorting (FACS). The approach is more rapid than prior art methods and avoids problems associated with the surface-expression of ligand fusion proteins employed with phage display.Type: GrantFiled: October 27, 2000Date of Patent: August 1, 2006Assignee: The Board of Regents of The University of Texas SystemInventors: Gang Chen, Andrew Hayhurst, Jeffrey G. Thomas, Brent L. Iverson, George Georgiou
-
Patent number: 7078218Abstract: Provided herein are methods for producing alphavirus replicon particles in high yield; replicon RNAs are electroporated into permissive cells, where the cells are at a relatively high density, together with at least one helper nucleic acid providing the necessary functions for packaging. After a growth period in appropriate medium, alphavirus replicon particles are harvested from the surfaces of the cells in which they were produced using a salt wash in which the salt concentration is from about 0.2 to about 5 M sodium chloride, calcium chloride, magnesium chloride, potassium chloride, ammonium acetate, ammonium bicarbonate, among others. After dilution, if necessary, the particles can be purified by a suitable chromatographic technique.Type: GrantFiled: December 12, 2003Date of Patent: July 18, 2006Assignee: AlphaVax, Inc.Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Harold Alterson, Jon Rayner, Kim Butler, Maureen F. Maughan
-
Patent number: 7078043Abstract: A non-naturally occurring variant of a C-terminal fragment of a Plasmodium merozoite surface protein-1 (MSP-1) wherein said variant has (i) a reduced affinity, compared with a naturally occurring Plasmodium MSP-119, for at least one first antibody capable of blocking the binding of a second antibody, which second antibody inhibits the proteolytic cleavage of Plasmodium MSP-142 and (ii) substantially the same affinity for at least one third antibody compared with said naturally occurring Plasmodium MSP-119. which third antibody inhibits the proteolytic cleavage of Plasmodium MSP-142 is provided for use in an anti-malarial vaccine.Type: GrantFiled: October 16, 2001Date of Patent: July 18, 2006Assignee: Medical Research CouncilInventors: Anthony Holder, Berry Birdsall, James Feeney, William Morgan, Shabih Syed, Chairat Uthaipibull
-
Patent number: 7078507Abstract: Synthetic gene sequences encoding erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into the DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both.Type: GrantFiled: November 12, 2002Date of Patent: July 18, 2006Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: David Narum, Hong Liang, Steve Fuhrmann, B. Kim Lee Sim
-
Patent number: 7074913Abstract: The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotide molecules, and cells displaying no anthrax toxin receptor on an exterior surface of the cells-minus cell lines and animals. The present invention also relates to methods for identifying molecules that bind the anthrax toxin receptor and molecules that reduce the toxicity of anthrax toxin. Finally, the present invention provides methods for treating human and non-human animals suffering from anthrax.Type: GrantFiled: October 3, 2001Date of Patent: July 11, 2006Assignees: Wisconsin Alumni Research Foundation, President and Fellows of Harvard CollegeInventors: John A. T. Young, Kenneth A Bradley, R. John Collier, Jeremy S. Mogridge
-
Patent number: 7070989Abstract: The present invention provides a recombinant plasmid vector comprising a kanamycin resistance gene, a promoter, an endoxylanase signal sequence, a nucleotide sequence coding for an oligopeptide consisting of 13 amino acids including 6 consecutive histidine residues, and a human granulocyte colony stimulating factor(hG-CSF) gene; an E. coli transformed with the said vector; and, a process for producing complete hG-CSF protein with high purity from the protein pool secreted by the said microorganism.Type: GrantFiled: March 31, 2001Date of Patent: July 4, 2006Assignee: Korea Advanced Institute of Science and TechnologyInventors: Sang-Yup Lee, Ki-Jun Jeong
-
Patent number: 7070792Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding full-length, 5?-truncated or 3?-truncated 76 kDa protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 76 kDa protein gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: June 30, 2003Date of Patent: July 4, 2006Assignee: Sanofi Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Patent number: 7070793Abstract: To provide a novel antigenic protein and a nucleic acid encoding the antigenic protein, which are useful for prophylaxis, treatment and diagnosis of diseases caused by fungi including Candida albicans. An antigenic protein characterized in that the antigenic protein is recognized by antiserum derived from a mammal having Candida albicans-infection resistance; and a nucleic acid encoding an antigenic protein which is recognized by antiserum derived from a mammal having Candida albicans-infection resistance.Type: GrantFiled: September 28, 1998Date of Patent: July 4, 2006Assignee: Takara Bio, Inc.Inventors: Kazutoh Takesako, Shigetoshi Mizutani, Masahiro Endo, Junko Ogawa, Takashi Okado, Ikunoshin Kato
-
Patent number: 7064195Abstract: The present invention relates to fusion proteins of Mycobacterium tuberculosis antigens. In particular, it relates to two fusion proteins, each of which contains three individual M. tuberculosis antigens, and a fusion protein of two M. tuberculosis antigens, their coding sequences, and methods for their use in the treatment and prevention of tuberculosis.Type: GrantFiled: February 5, 2003Date of Patent: June 20, 2006Assignee: CorixaInventors: Yasir Skeiky, Mark Alderson, Antonio Campos-Neto
-
Patent number: 7060276Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: March 25, 2002Date of Patent: June 13, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
-
Patent number: 7056510Abstract: The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneunoniae. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of Streptococcus pneumoniae. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting Streptococcus nucleic acids, polypeptides and antibodies in a biological sample.Type: GrantFiled: October 30, 1997Date of Patent: June 6, 2006Assignee: Human Genome Sciences, Inc.Inventors: Gil H. Choi, Charles A. Kunsch, Steven C. Barash, Patrick J. Dillon, Brian Dougherty, Michael R. Fannon, Craig A. Rosen
-
Patent number: 7056700Abstract: The disclosure below provides a protein export system for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced.Type: GrantFiled: November 23, 2001Date of Patent: June 6, 2006Assignee: University of MarylandInventor: James E. Galen
-
Patent number: 7049098Abstract: The present invention relates to linear expression elements (LEEs) and circular expression elements (CEEs), which are useful in a variety of molecular biology protocols. Specifically, the invention relates to the use of LEEs and CEEs to screen for gene function, biological effects of gene function, antigens, and promoter function. The invention also provides methods of producing proteins, antibodies, antigens, and vaccines. Also, the invention relates to methods of making LEEs and CEEs, and LEEs and CEEs produced by such methods.Type: GrantFiled: February 15, 2002Date of Patent: May 23, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Kathryn F. Sykes, Stephen Albert Johnston